Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3B, Single-Arm, Open-Label Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids or Moderate to Severe Pain Associated With Endometriosis

NCT05862272 is registered in ClinicalTrials.gov with Sumitomo Pharma Switzerland GmbH as lead sponsor.

NCT NCT05862272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05862272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3B, Single-Arm, Open-Label Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids or Moderate to Severe Pain Associated With Endometriosis
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Phase
Phase 3
Overall status
Recruiting
Start date
August 14, 2023
Completion date
September 30, 2030
Enrollment
1,000 (estimated)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis, uterine fibroids